Regeneron Announces Investor Conference Presentations
25 Outubro 2023 - 5:05PM
Regeneron Pharmaceuticals, Inc. (NASDAQ:
REGN)
will webcast management participation as follows:
- BMO Biopharma Spotlight Series: Oncology at 9:30 a.m. ET on
Wednesday, November 8, 2023
- Truist Securities BioPharma Symposium at 3:20 p.m. ET on
Wednesday, November 8, 2023
- UBS Biopharma Conference at 11:00 a.m. ET on Thursday, November
9, 2023
- Jefferies London Healthcare Conference at 2:30 p.m. GMT (9:30
a.m. ET) on Wednesday, November 15, 2023
The sessions may be accessed from the "Investors
& Media" page of Regeneron's website at
https://investor.regeneron.com/events-and-presentations. Replays
and transcripts of the webcasts will be archived on the Company's
website for at least 30 days.
About Regeneron Regeneron is a
leading biotechnology company that invents, develops, and
commercializes life-transforming medicines for people with serious
diseases. Founded and led for 35 years by physician-scientists,
Regeneron's unique ability to repeatedly and consistently translate
science into medicine has led to numerous FDA-approved treatments
and product candidates in development, almost all of which were
homegrown in Regeneron's laboratories. Regeneron's medicines and
pipeline are designed to help patients with eye diseases, allergic
and inflammatory diseases, cancer, cardiovascular and metabolic
diseases, hematologic conditions, infectious diseases, and
rare diseases.
Regeneron is accelerating and improving the
traditional drug development process through its
proprietary VelociSuite® technologies, such
as VelocImmune®, which uses unique genetically
humanized mice to produce optimized fully
human antibodies and bispecific antibodies, and through
ambitious research initiatives such as the Regeneron Genetics
Center®, which is conducting one of the largest genetics sequencing
efforts in the world.
For additional information about Regeneron, please
visit www.regeneron.com or follow Regeneron on
LinkedIn.
Contact Information: Investor
Relations Ryan Crowe 914.847.8790 ryan.crowe@regeneron.com
Regeneron Pharmaceuticals (NASDAQ:REGN)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Regeneron Pharmaceuticals (NASDAQ:REGN)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024